AANEM News Express

AANEM News Express

Science News: Myotonic Muscular Dystrophy Type 2 in CT, USA: A Single-Center Experience With 50 Patients

Submitted by: Francisco Gomez, MD
Edited by: Francisco Gomez, MD

Roy B, Wu Q, Whitaker CH, Felice KJ. Myotonic Muscular Dystrophy Type 2 in CT, USA: A Single-Center Experience With 50 Patients. J Clin Neuromuscul Dis. 2021;22(3):135-146. doi:10.1097/CND.0000000000000340

Summary: Myotonic muscular dystrophy type 2 (DM2) is a an autosomal dominant genetic disease stemming from expansion of the first intron of the Cellular Nucleic acid Binding Protein (CNBP) gene which encodes for a zinc finger protein. This disease tends to course with wasting muscle weakness, characteristic myotonia, and cataracts.

The authors report a 27 year, single center case series involving 50 patients diagnosed with Myotonic Dystrophy type 2, reporting incidence and prevalence of several findings:

Age of onset ranged 15-72 years, with an average time from clinical debut to diagnosis of 7.4 years, furthermore:
•    18% presented with clinical myotonia, however, electromyographic myotonia was found in 97% of patients.
•    62% debuted with proximal extremity weakness.
•    30% presented generalized weakness while 20% exhibited no weakness at all.
•    There was no correlation between number of repeats and pathologic changes, however there was a correlation noted between degree of muscle weakness and muscle pathologic changes.
•    A 1% yearly decline in Medical Research Council scores was observed in 21 patients followed for 2 or more years.

View Related News Stories:

  EducationScience NewsNSEB

Recent AANEM News

Remembering George Kraft, MD, MS

The American Clinical Neurophysiology Society to Hold Another Townhall Meeting of Clinical Neurophysiology, Epilepsy, and Neuromuscular Fellowship Program Directors

Science News: Amyotrophic Lateral Sclerosis and Noninvasive Positive Pressure Ventilatory Support: "Nasal Noninvasive Ventilation" or "Noninvasive Ventilatory Support"?

CMS Finalizes Updates to Physician Fee Schedule

Advocacy in Action: State Liaison Leads the Way for Patient Advocacy in Washington and Beyond